- Molecular NameSalbutamol
- SynonymAlbuterol; Albuterol Sulfate; Albuterol Sulphate; Levalbuterol; Salbutamol Sulfate; Salbutamol Sulphate
- Weight239.315
- Drugbank_IDDB01001
- ACS_NO18559-94-9
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.19
- pka9.3
- LogD (pH=7, predicted)-1.82
- Solubility (experiment)0.0144 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.62
- LogSw (predicted, AB/LogsW2.0)33.06
- Sw (mg/ml) (predicted, ACD/Labs)53.49
- No.of HBond Donors4
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA72.72
- StatusFDA approved
- AdministrationOral, inhalational, IV
- PharmacologyA short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
- Absorption_value83.0
- Absorption (description)Systemic absorption is rapid following aerosol administration.
- Caco_2N/A
- Bioavailability44.0
- Protein binding10.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to albuterol 4'-O-sulfate.
- Half life1.6 h
- ExcretionRenal; Approximately 72% of the inhaled dose is excreted within 24 hours in the urine, and consists of 28% as unchanged drug and 44% as metabolite.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityCases of urticaria, angioedema, rash, bronchospasm, hoarseness, oropharyngeal edema, and arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles) have been reported after the use of albuterol.
- LD50 (rat)N/A
- LD50 (mouse)LD50=1100 mg/kg